Pagé E L, Desnoyers S, Létourneau I J, Keown K, Jackson A, Ouellette M
Canadian Institutes of Health Research, Institute of Infection and Immunity, Québec, QC.
Canadian Institutes of Health Research, Ottawa, ON.
Can Commun Dis Rep. 2015 Nov 19;41(Suppl 5):11-15. doi: 10.14745/ccdr.v41is5a03.
Antimicrobial resistance (AMR) has been a research priority for the Canadian Institutes of Health Research (CIHR), Institute of Infection and Immunity (III) since its inception, and a number of strategic research initiatives have been launched to address this global health problem by promoting and supporting research related to mechanisms and processes that impact the emergence and spread of resistance among individuals and within the environment. Here we will present research initiatives on AMR led by CIHR-III, which include national programs as well as international partnerships with the United Kingdom and the European Union, in addition to interesting outcomes of these initiatives.
自成立以来，抗菌药物耐药性（AMR）一直是加拿大卫生研究院（CIHR）感染与免疫研究所（III）的研究重点。通过促进和支持与影响个体及环境中耐药性产生和传播的机制及过程相关的研究，已经启动了多项战略研究计划来解决这一全球健康问题。在此，我们将介绍由CIHR-III牵头的关于抗菌药物耐药性的研究计划，其中包括国家项目以及与英国和欧盟的国际合作关系，此外还将介绍这些计划取得的有趣成果。
